UB Paderborn / Katalog / Suche / in CDI

Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity

Cancer cell, 2014-08, Vol.26 (2), p.177-189

2014

Link zum Volltext

Verfügbarkeit prüfen

Death receptor agonist therapies for cancer, which is the right TRAIL?

Cytokine & growth factor reviews, 2014-04, Vol.25 (2), p.185-193

Holland, Pamela M

2014

Link zum Volltext

Verfügbarkeit prüfen

Endogenous IL-27 during toxoplasmosis limits early monocyte responses and their inflammatory activation by pathological T cells

mBio, 2024-03, Vol.15 (3), p.e0008324-e0008324

2024

Link zum Volltext

Verfügbarkeit prüfen

Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL

Cancer letters, 2013-05, Vol.332 (2), p.156-162

Holland, Pamela M

2013

Link zum Volltext

Verfügbarkeit prüfen

Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis

Cancer biology & therapy, 2010-04, Vol.9 (7), p.539-550

2010

Link zum Volltext

Verfügbarkeit prüfen

Non‐Redundant Roles of T Cell Costimulation Pathways in Inflammatory Arthritis Revealed by Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN‐101)

Arthritis & rheumatology (Hoboken, N.J.), 2023-08, Vol.75 (8), p.1344-1356

2023

Link zum Volltext

Verfügbarkeit prüfen

Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell–Related Autoimmune Diseases

Arthritis & rheumatology (Hoboken, N.J.), 2023-07, Vol.75 (7), p.1187-1202

2023

Link zum Volltext

Verfügbarkeit prüfen

Multiple Signaling Pathways for the Activation of JNK in Mast Cells: Involvement of Bruton's Tyrosine Kinase, Protein Kinase C, and JNK Kinases, SEK1 and MKK7

The Journal of immunology (1950), 1998-08, Vol.161 (4), p.1795-1802

1998

Link zum Volltext

Verfügbarkeit prüfen

Purification, Cloning, and Characterization of Nek8, a Novel NIMA-related Kinase, and Its Candidate Substrate Bicd2

The Journal of biological chemistry, 2002-05, Vol.277 (18), p.16229-16240

2002

Link zum Volltext

Verfügbarkeit prüfen

RIP4 Regulates Epidermal Differentiation and Cutaneous Inflammation

Journal of investigative dermatology, 2010-01, Vol.130 (1), p.102-112

2010

Link zum Volltext

Verfügbarkeit prüfen

Protein modification: Docking sites for kinases

Current biology, 1999-05, Vol.9 (9), p.R329-R331

1999

Link zum Volltext

Verfügbarkeit prüfen

Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells

Apoptosis (London), 2007-08, Vol.12 (8), p.1465-1478

2007

Link zum Volltext

Verfügbarkeit prüfen

RIP4 Is an Ankyrin Repeat-Containing Kinase Essential for Keratinocyte Differentiation

Current biology, 2002-08, Vol.12 (16), p.1424-1428

2002

Link zum Volltext

Verfügbarkeit prüfen

MKK7 Is A Stress-activated Mitogen-activated Protein Kinase Kinase Functionally Related to hemipterous

The Journal of biological chemistry, 1997-10, Vol.272 (40), p.24994-24998

1997

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4548: SRF813, a fully human monoclonal antibody targeting the inhibitory receptor CD112R, enhances immune cell activation and demonstrates preclinical in vivo anti-tumor activity

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.4548-4548

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1802: CD39 inhibition shapes the transcriptional landscape of myeloid cells and induces proinflammatory states in the CT26 syngeneic tumor model

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1802-1802

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract 6639: SRF617, a potent enzymatic inhibitor of CD39, demonstrates single-agent activity and cooperates with various cancer therapies in both solid tumor and hematologic malignancies

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.6639-6639

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4550: Increased IL-27 is associated with poor prognosis in renal cell carcinoma and supports use of SRF388, a first-in-class IL-27p28 blocking antibody, to counteract IL-27-mediated immunosuppression in this setting

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.4550-4550

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 558: MERTK-specific antibodies that have therapeutic antitumor activity in mice disrupt the integrity of the retinal pigmented epithelium in cynomolgus monkeys

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.558-558

2019

Link zum Volltext

Verfügbarkeit prüfen

Targeted Inhibition of CD47-Sirp Alpha Requires Fc-Fc Gamma Receptor Interactions to Maximize Phagocytosis in T-Cell Lymphomas

Blood, 2018-11, Vol.132 (Supplement 1), p.339-339

2018

Link zum Volltext

Verfügbarkeit prüfen

The Fully Human Anti-CD47 Antibody SRF231 Has Dual-Mechanism Antitumor Activity Against Chronic Lymphocytic Leukemia (CLL) Cells and Increases the Activity of Both Rituximab and Venetoclax

Blood, 2018-11, Vol.132 (Supplement 1), p.4393-4393

2018

Link zum Volltext

Verfügbarkeit prüfen

Protein kinase C-associated kinase is not required for the development of peripheral B lymphocyte populations

Molecular Immunology, 2006-04, Vol.43 (10), p.1694-1699

2006

Link zum Volltext

Verfügbarkeit prüfen

CD47 Monoclonal Antibody SRF231 Is a Potent Inducer of Macrophage-Mediated Tumor Cell Phagocytosis and Reduces Tumor Burden in Murine Models of Hematologic Malignancies

Blood, 2016-12, Vol.128 (22), p.1843-1843

2016

Link zum Volltext

Verfügbarkeit prüfen

Correction: Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers

Journal for immunotherapy of cancer, 2020-04, Vol.8 (1), p.e0737-3corr1

2020

Link zum Volltext

Verfügbarkeit prüfen

Correction: Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

Journal for immunotherapy of cancer, 2020-04, Vol.8 (1), p.e000878corr1

2020

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity

Death receptor agonist therapies for cancer, which is the right TRAIL?

Endogenous IL-27 during toxoplasmosis limits early monocyte responses and their inflammatory activation by pathological T cells

Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL

Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis

Non‐Redundant Roles of T Cell Costimulation Pathways in Inflammatory Arthritis Revealed by Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN‐101)

Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell–Related Autoimmune Diseases

Multiple Signaling Pathways for the Activation of JNK in Mast Cells: Involvement of Bruton's Tyrosine Kinase, Protein Kinase C, and JNK Kinases, SEK1 and MKK7

Purification, Cloning, and Characterization of Nek8, a Novel NIMA-related Kinase, and Its Candidate Substrate Bicd2

RIP4 Regulates Epidermal Differentiation and Cutaneous Inflammation

Protein modification: Docking sites for kinases

Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells

RIP4 Is an Ankyrin Repeat-Containing Kinase Essential for Keratinocyte Differentiation

MKK7 Is A Stress-activated Mitogen-activated Protein Kinase Kinase Functionally Related to hemipterous

Abstract 4548: SRF813, a fully human monoclonal antibody targeting the inhibitory receptor CD112R, enhances immune cell activation and demonstrates preclinical in vivo anti-tumor activity

Abstract 1802: CD39 inhibition shapes the transcriptional landscape of myeloid cells and induces proinflammatory states in the CT26 syngeneic tumor model

Abstract 6639: SRF617, a potent enzymatic inhibitor of CD39, demonstrates single-agent activity and cooperates with various cancer therapies in both solid tumor and hematologic malignancies

Abstract 4550: Increased IL-27 is associated with poor prognosis in renal cell carcinoma and supports use of SRF388, a first-in-class IL-27p28 blocking antibody, to counteract IL-27-mediated immunosuppression in this setting

Abstract 558: MERTK-specific antibodies that have therapeutic antitumor activity in mice disrupt the integrity of the retinal pigmented epithelium in cynomolgus monkeys

Targeted Inhibition of CD47-Sirp Alpha Requires Fc-Fc Gamma Receptor Interactions to Maximize Phagocytosis in T-Cell Lymphomas

The Fully Human Anti-CD47 Antibody SRF231 Has Dual-Mechanism Antitumor Activity Against Chronic Lymphocytic Leukemia (CLL) Cells and Increases the Activity of Both Rituximab and Venetoclax

Protein kinase C-associated kinase is not required for the development of peripheral B lymphocyte populations

CD47 Monoclonal Antibody SRF231 Is a Potent Inducer of Macrophage-Mediated Tumor Cell Phagocytosis and Reduces Tumor Burden in Murine Models of Hematologic Malignancies

Correction: Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers

Correction: Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

Suchergebnisse filtern